Ohyagi A, Hirose K, Watanabe Y, Nakai T, Tsujimoto S, Doyama K, Suzuki Y, Okazaki S, Hirai M
Clin Cardiol. 1987 Aug;10(8):453-6. doi: 10.1002/clc.4960100809.
Intracoronary thrombolysis is a logical therapeutic method and one of the challenging new treatments of acute myocardial infarction. However, a wide dose range of urokinase has been reported, and the optimal dose has not yet been established. In this study the fibrinolytic activity in patients with recanalized coronary arteries was compared with that in those with nonrecanalized arteries. The mean doses of urokinase in the recanalized and non-recanalized groups were 910,700 +/- 161,730 international units (IU) and 1,008,000 +/- 151,800 IU, respectively. The fibrinolytic activity was measured with alpha 2-plasmin inhibitor, alpha 2-macroglobulin, fibrinogen, plasminogen, and fibrin degradation products. No significant difference was observed in the fibrinolytic activity between the recanalized and nonrecanalized groups. Because the fibrinolytic activity in the two groups was thought to be activated sufficiently and to a similar degree, it appears that 1,000,000 IU of urokinase is adequate for intracoronary thrombolysis and larger doses cannot be expected to result in a higher rate of recanalization.
冠状动脉内溶栓是一种合理的治疗方法,也是急性心肌梗死具有挑战性的新治疗方法之一。然而,已有报道尿激酶的剂量范围很广,最佳剂量尚未确定。在本研究中,对冠状动脉再通患者和未再通患者的纤溶活性进行了比较。再通组和未再通组尿激酶的平均剂量分别为910,700±161,730国际单位(IU)和1,008,000±151,800 IU。用α2 - 纤溶酶抑制剂、α2 - 巨球蛋白、纤维蛋白原、纤溶酶原和纤维蛋白降解产物测量纤溶活性。再通组和未再通组之间的纤溶活性未观察到显著差异。由于认为两组的纤溶活性已被充分激活且程度相似,因此似乎1,000,000 IU的尿激酶足以进行冠状动脉内溶栓,预计更大剂量不会导致更高的再通率。